Skip to main content
. 2008 Apr 14;112(4):975–980. doi: 10.1182/blood-2008-02-140582

Figure 3.

Figure 3

Survival of patients receiving fludarabine (F), fludarabine and cyclophosphamide or mitoxantrone (FC/M), and FCR as initial therapy of CLL at the M. D. Anderson Cancer Center. Six-year overall survivals were 54%, 59%, and 77%, respectively.